ArticleThe American journal of gastroenterology2017
Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.Clinical and translational gastroenterology · 2020Trial
- Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.The American journal of gastroenterology · 2019Trial
- IBS stress reactivity phenotype is associated with blood transcriptome profiles and microstructural and functional brain changes.Neurobiology of stress · 2026Article
- Usability study to guide the development of a cognitive behavioral therapy mobile application for reducing irritable bowel syndrome symptoms.BioPsychoSocial medicine · 2026Article
- From Desperation to Sustainability: A Qualitative Exploration of Drivers and Barriers to Time-Restricted Eating in IBS Treatment.Nutrients · 2026Article
- Psychological value theory: predicting health-seeking behavior from symptom perception.Journal of behavioral medicine · 2025Article
- Fecal calprotectin levels in patients with fibromyalgia: A cross-sectional study.Archives of rheumatology · 2024Article
- A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.Gastroenterology & hepatology · 2024Article
- Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation.The journal of headache and pain · 2024Article
- Irritable Bowel Syndrome Patient Experience: A Survey of Patient-Reported Symptoms by Irritable Bowel Syndrome Subtype and Impact on Quality of Life.Journal of the Canadian Association of Gastroenterology · 2023Article
- Distinct Food Triggers for Migraine, Medication Overuse Headache and Irritable Bowel Syndrome.Journal of clinical medicine · 2023Article
- Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity.Pharmaceutics · 2023Article
- A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.Advances in therapy · 2022Review
- Special Considerations for the Management of Disorders of Gut-Brain Interaction in Older Adults.Current treatment options in gastroenterology · 2022Review
- Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population.United European gastroenterology journal · 2021Article
- High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation.JCI insight · 2021Article
- Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial.Chinese medicine · 2021Article
- The Impact of Diagnostic Status on Quality of Life in Irritable Bowel Syndrome.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.The American journal of gastroenterology · 2021Review
- Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan.Frontiers in pharmacology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIrritable bowel syndrome (IBS) is a functional bowel disorder characterized by symptoms including abdominal pain and altered bowel function. Up to 75% of individuals with IBS may be undiagnosed. The aim of this study was to characterize symptoms, healthcare utilization, and treatments in populations with both diagnosed and undiagnosed IBS.
methodsAn online survey was conducted to compare gastrointestinal (GI) symptoms, healthcare visits, well-being, symptom management, and treatment satisfaction in individuals with and without medically diagnosed IBS (Rome III criteria). Symptom severity, disruptiveness, and treatment satisfaction were rated using a 7-point scale. Adjustments to daily life were determined by predefined survey responses.
resultsA total of 1,924 individuals with a history of GI symptoms were eligible and completed the survey. Of these, 1,094 individuals (56.9%) met the criteria for IBS; 830 individuals (43.1%) had no medical diagnosis of IBS despite meeting diagnostic criteria. Most participants received a diagnosis from either gastroenterologists (45%) or primary care physicians (42%). A greater percentage of diagnosed patients had severe GI symptoms (score ≥6) vs. undiagnosed individuals (16% vs. 8%, respectively; P<0.05); diagnosed patients were more likely to report that GI symptoms adversely affected their quality of life. Approximately 40% of participants received IBS-related treatment from primary care physicians; 26% and 43% of diagnosed and undiagnosed individuals, respectively, were not receiving treatment for GI symptoms.
conclusionsMany individuals with IBS-related symptoms have not been medically diagnosed with IBS. IBS-related symptoms impact quality of life, yet more than one-third of individuals are not receiving treatment for IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.